Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) With Chemotherapy As Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients With Tumor Cell PD-L1 Expression ≥1%

The decision was based on results from the Phase III CheckMate -816 trial, in which three cycles of Opdivo with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival and pathologic complete response compared to chemotherapy alone when administered before surgery.